Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule

Highlights • Cervarix® is a licenced 3-dose HPV vaccine for preventing cervical cancer. • Avidity indices (AIs) can inform on the quality of HPV-specific antibody responses. • At least 1.27-fold changes in AIs were detected in samples from Cervarix ® trials. • AIs appeared similar after the final do...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-05, Vol.32 (26), p.3232-3236
Hauptverfasser:	Boxus, Mathieu, Lockman, Laurence, Fochesato, Michel, Lorin, Clarisse, Thomas, Florence, Giannini, Sandra L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Allergy and Immunology Antibodies Antibodies, Viral - blood Antibody Affinity Applied microbiology Avidity Biological and medical sciences Cervical cancer Child Enzyme-Linked Immunosorbent Assay Female Fundamental and applied biological sciences. Psychology Human papillomavirus Humans Immunization Schedule Medical sciences Microbiology Middle Aged Miscellaneous Papillomavirus Infections - prevention & control Papillomavirus Vaccines - immunology Randomized Controlled Trials as Topic Tumors Uterine Cervical Neoplasms - prevention & control Vaccine Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Virus-Like Particle - immunology Virology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Cervarix® is a licenced 3-dose HPV vaccine for preventing cervical cancer. • Avidity indices (AIs) can inform on the quality of HPV-specific antibody responses. • At least 1.27-fold changes in AIs were detected in samples from Cervarix ® trials. • AIs appeared similar after the final dose of 2 (0–6 month)- or 3 (0–1–6 month)-dose regimens. • This study supports the adoption of a 2-dose regimen in 9–14 year old girls.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.04.005